Cancer Gene Therapy

REPORT HIGHLIGHTS

Global Cancer Gene Therapy Market to Reach US$19.9 Billion by 2032

The global market for Cancer Gene Therapy estimated at US$5.3 Billion in the year 2025, is expected to reach US$19.9 Billion by 2032, growing at a CAGR of 20.8% over the analysis period 2025-2032. Large B-Cell Lymphoma Indication, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Multiple Myeloma Indication segment is estimated at 22.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 19.7% CAGR

The Cancer Gene Therapy market in the U.S. is estimated at US$1.6 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2032 trailing a CAGR of 19.7% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.5% and 17.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Global Cancer Gene Therapy Market - Key Trends and Drivers Summarized

Why Is Cancer Gene Therapy Revolutionizing Cancer Treatment?

Cancer gene therapy represents a groundbreaking approach in the fight against cancer, offering innovative solutions by targeting the genetic root causes of cancer rather than just treating the symptoms. Unlike traditional treatments like chemotherapy and radiation, which attack both healthy and cancerous cells, gene therapy aims to alter or repair the genes that cause cancer to develop and spread. This method provides a more precise and potentially less harmful alternative. Techniques such as gene editing, using CRISPR technology, or delivering therapeutic genes via viral vectors, allow doctors to replace mutated genes, introduce new genes that help fight cancer, or make cancer cells more recognizable to the immune system. The impact of cancer gene therapy extends beyond treatment, as it offers long-term remission and, in some cases, even a cure. The ability to manipulate the genetic foundation of cancer represents a monumental shift in how we approach treatment, transforming cancer care from a one-size-fits-all model to a more personalized and effective strategy.

How Are Technological Advances Shaping Cancer Gene Therapy?

Technological innovation is the driving force behind the rapid advancements in cancer gene therapy. The most significant development in recent years is the rise of CRISPR-Cas9, a gene-editing technology that allows scientists to precisely modify genes within cancer cells. This tool has revolutionized the field, enabling researchers to either correct mutations or knock out genes that contribute to cancer progression. Viral vectors, which deliver therapeutic genes directly into cancer cells, are also becoming more efficient and safer, thanks to innovations in vector engineering. These vectors are crucial in gene therapy as they provide a way to transport genetic material into cells without causing harm to the patient. Additionally, next-generation sequencing (NGS) is advancing cancer gene therapy by offering deeper insights into the genetic mutations driving individual cancers. This technology allows for highly personalized treatments based on the specific genetic profile of a patient’s cancer. Artificial intelligence and machine learning are also playing pivotal roles by analyzing large datasets and predicting the outcomes of gene therapy interventions, making it easier to design effective treatments. These technological advances have not only made gene therapy more accessible but have also improved its safety and efficacy, driving its growth in the oncology field.

What Are the Emerging Trends and Challenges in Cancer Gene Therapy?

Several key trends are currently shaping the cancer gene therapy market, each contributing to the expansion and refinement of this innovative treatment modality. One of the most prominent trends is the growing focus on personalized medicine. As cancer gene therapy becomes more tailored to individual patients based on their genetic makeup, the industry is seeing a shift towards highly customized treatments that offer better outcomes. Another trend is the increasing use of immunotherapy in combination with gene therapy. By enhancing the immune system`s ability to recognize and destroy cancer cells, these therapies are becoming more effective and versatile in treating various cancer types. However, despite these advancements, cancer gene therapy faces several challenges. One significant issue is the high cost of treatment, which can be prohibitive for many patients and healthcare systems. The complexity of developing gene therapies, including regulatory hurdles and long timelines for clinical trials, also poses a challenge to broader market adoption. Additionally, ensuring the safety of gene therapies remains a concern, as there is always a risk of off-target effects or unwanted immune responses. Despite these obstacles, the rapid pace of innovation and growing understanding of cancer genetics continue to drive the development of cancer gene therapies.

What Are the Key Growth Drivers in the Cancer Gene Therapy Market?

The growth in the cancer gene therapy market is driven by several factors, including advances in gene editing technologies, the increasing focus on personalized medicine, and the rising incidence of cancer globally. One of the most significant drivers is the development of tools like CRISPR-Cas9 and other gene-editing technologies, which have greatly enhanced the precision and effectiveness of cancer gene therapy. The push towards personalized medicine is also a major growth factor, as more patients and healthcare providers seek treatments that are tailored to the individual genetic mutations driving a patient’s cancer. This demand for personalized, targeted treatments has led to increased investment in the research and development of gene therapies. Additionally, the rising prevalence of cancer worldwide, particularly in aging populations, is contributing to the growing need for innovative therapies that can offer long-term solutions or even cures. Immunotherapy advancements, where gene therapy is used to modify immune cells to better fight cancer, are further expanding the therapeutic landscape. Regulatory approvals and breakthrough designations for certain gene therapies are accelerating their entry into the market, allowing for faster adoption. As a result, the combination of technological innovation, personalized approaches, and increasing cancer cases continues to fuel the robust growth of the cancer gene therapy market.

SCOPE OF STUDY:

The report analyzes the Cancer Gene Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Indication (Large B-Cell Lymphoma Indication, Multiple Myeloma Indication, Acute Lymphoblastic Leukemia Indication, Melanoma Indication, Other Indications); Administration Route (Intravenous Administration Route, Other Administration Routes); Vector Type (Lentivirus Vector Type, RetroVirus & Gamma RetroVirus Vector Type, AAV Vector Type, Modified Herpes Simplex Virus Vector Type, Adenovirus Vector Type, Other Vector Types)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Adaptimmune Limited
• Candel Therapeutics
• Gilead Sciences, Inc.
• Genelux Corporation
• GlaxoSmithKline PLC
• Krystal Biotech, Inc.
• Merck & Co., Inc.
• Shanghai Sunway Biotech Co., Ltd.
• Shenzhen SiBiono GeneTech Co., Ltd.
• Novartis AG

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more